82 related articles for article (PubMed ID: 12171895)
1. Antibody localization to B-cell lymphoma xenografts in immunodeficient mice: importance of using residualizing radiolabels.
Michel RB; Ochakovskaya R; Mattes MJ
Clin Cancer Res; 2002 Aug; 8(8):2632-9. PubMed ID: 12171895
[TBL] [Abstract][Full Text] [Related]
2. Single-cell cytotoxicity with radiolabeled antibodies.
Ong GL; Elsamra SE; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jan; 7(1):192-201. PubMed ID: 11205908
[TBL] [Abstract][Full Text] [Related]
3. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
Stein R; Goldenberg DM; Thorpe SR; Basu A; Mattes MJ
Cancer Res; 1995 Jul; 55(14):3132-9. PubMed ID: 7606734
[TBL] [Abstract][Full Text] [Related]
4. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium.
Ochakovskaya R; Osorio L; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2001 Jun; 7(6):1505-10. PubMed ID: 11410483
[TBL] [Abstract][Full Text] [Related]
5. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
6. Improved iodine radiolabels for monoclonal antibody therapy.
Stein R; Govindan SV; Mattes MJ; Chen S; Reed L; Newsome G; McBride BJ; Griffiths GL; Hansen HJ; Goldenberg DM
Cancer Res; 2003 Jan; 63(1):111-8. PubMed ID: 12517786
[TBL] [Abstract][Full Text] [Related]
7. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
Michel RB; Rosario AV; Andrews PM; Goldenberg DM; Mattes MJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):777-86. PubMed ID: 15701868
[TBL] [Abstract][Full Text] [Related]
8. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill.
Michel RB; Brechbiel MW; Mattes MJ
J Nucl Med; 2003 Apr; 44(4):632-40. PubMed ID: 12679410
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels.
Patel S; Stein R; Ong GL; Goldenberg DM; Mattes MJ
J Nucl Med; 1999 Aug; 40(8):1392-401. PubMed ID: 10450693
[TBL] [Abstract][Full Text] [Related]
10. Localization of an antibody to CD74 (MHC class II invariant chain) to human B cell lymphoma xenografts in nude mice.
Shih L; Ong GL; Burton J; Mishina D; Goldenberg DM; Mattes MJ
Cancer Immunol Immunother; 2000 Jul; 49(4-5):208-16. PubMed ID: 10941903
[TBL] [Abstract][Full Text] [Related]
11. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
[TBL] [Abstract][Full Text] [Related]
12. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.
Mattes MJ; Shih LB; Govindan SV; Sharkey RM; Ong GL; Xuan H; Goldenberg DM
Int J Cancer; 1997 May; 71(3):429-35. PubMed ID: 9139880
[TBL] [Abstract][Full Text] [Related]
13. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells.
Michel RB; Mattes MJ
Clin Cancer Res; 2002 Aug; 8(8):2701-13. PubMed ID: 12171904
[TBL] [Abstract][Full Text] [Related]
14. Manipulation of blood clearance to optimize delivery of residualizing label-antibody conjugates to tumor cells in vivo.
Stein R; Goldenberg DM; Ong GL; Thorpe SR; Mattes MJ
J Nucl Med; 1997 Sep; 38(9):1392-400. PubMed ID: 9293796
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
Michel RB; Andrews PM; Rosario AV; Goldenberg DM; Mattes MJ
Nucl Med Biol; 2005 Apr; 32(3):269-78. PubMed ID: 15820762
[TBL] [Abstract][Full Text] [Related]
16. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
17. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
[TBL] [Abstract][Full Text] [Related]
18. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Vallera DA; Brechbiel MW; Burns LJ; Panoskaltsis-Mortari A; Dusenbery KE; Clohisy DR; Vitetta ES
Clin Cancer Res; 2005 Nov; 11(21):7920-8. PubMed ID: 16278417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]